KR20080031738A - 1,4-벤조티아제핀 1,1-디옥사이드 유도체, 이의 제조방법,이를 포함하는 약제 및 고지혈증 치료제로서의 이의 용도 - Google Patents
1,4-벤조티아제핀 1,1-디옥사이드 유도체, 이의 제조방법,이를 포함하는 약제 및 고지혈증 치료제로서의 이의 용도 Download PDFInfo
- Publication number
- KR20080031738A KR20080031738A KR1020087001183A KR20087001183A KR20080031738A KR 20080031738 A KR20080031738 A KR 20080031738A KR 1020087001183 A KR1020087001183 A KR 1020087001183A KR 20087001183 A KR20087001183 A KR 20087001183A KR 20080031738 A KR20080031738 A KR 20080031738A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- agonists
- medicament
- inhibitors
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 122
- 239000003814 drug Substances 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 5
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract 2
- IVGHNDNOFMTFMK-UHFFFAOYSA-N 1$l^{6},4-benzothiazepine 1,1-dioxide Chemical class O=S1(=O)C=CN=CC2=CC=CC=C12 IVGHNDNOFMTFMK-UHFFFAOYSA-N 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000000556 agonist Substances 0.000 claims description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 17
- 239000005557 antagonist Substances 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 6
- 102000016267 Leptin Human genes 0.000 claims description 5
- 108010092277 Leptin Proteins 0.000 claims description 5
- 229940100389 Sulfonylurea Drugs 0.000 claims description 5
- 229940039781 leptin Drugs 0.000 claims description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 3
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 3
- 102000023984 PPAR alpha Human genes 0.000 claims description 3
- 108010028924 PPAR alpha Proteins 0.000 claims description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
- 102000004257 Potassium Channel Human genes 0.000 claims description 3
- 102000005630 Urocortins Human genes 0.000 claims description 3
- 108010059705 Urocortins Proteins 0.000 claims description 3
- 229940025084 amphetamine Drugs 0.000 claims description 3
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- -1 lipase inhibitors Substances 0.000 claims description 3
- 229950004994 meglitinide Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 108020001213 potassium channel Proteins 0.000 claims description 3
- 239000000777 urocortin Substances 0.000 claims description 3
- 102000004146 ATP citrate synthases Human genes 0.000 claims description 2
- 108090000662 ATP citrate synthases Proteins 0.000 claims description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 102000013585 Bombesin Human genes 0.000 claims description 2
- 108010051479 Bombesin Proteins 0.000 claims description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims description 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 2
- 102000019432 Galanin Human genes 0.000 claims description 2
- 101800002068 Galanin Proteins 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 102000000853 LDL receptors Human genes 0.000 claims description 2
- 108010001831 LDL receptors Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 claims description 2
- 102000002512 Orexin Human genes 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
- 239000003392 amylase inhibitor Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 2
- 229960002802 bromocriptine Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940125753 fibrate Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 239000002697 lyase inhibitor Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 2
- 230000002474 noradrenergic effect Effects 0.000 claims description 2
- 108060005714 orexin Proteins 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 claims description 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940126558 11β-HSD1 inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 claims 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002658 neuropeptide Y receptor agonist Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 230000002295 serotoninergic effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000012131 assay buffer Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 101000970390 Homo sapiens Ileal sodium/bile acid cotransporter Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004597 dexfenfluramine Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- AKMNUCBQGHFICM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea Chemical compound C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 AKMNUCBQGHFICM-UHFFFAOYSA-N 0.000 description 2
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 2
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 0 CC(OC(C[C@](*=COC(C)=O)O[C@]1*)[C@]1OC(C)=O)=O Chemical compound CC(OC(C[C@](*=COC(C)=O)O[C@]1*)[C@]1OC(C)=O)=O 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091006614 SLC10A2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000003931 anilides Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 108091022863 bile acid binding Proteins 0.000 description 2
- 102000030904 bile acid binding Human genes 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960002354 repaglinide Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- BYUKMGPIDIWLAC-UHFFFAOYSA-N 1-[4-chloro-3-(methylsulfonylmethyl)phenyl]-2-[2-[(2,3-dimethyl-1h-indol-6-yl)oxy]ethylamino]ethanol;hydrochloride Chemical compound Cl.C=1C=C2C(C)=C(C)NC2=CC=1OCCNCC(O)C1=CC=C(Cl)C(CS(C)(=O)=O)=C1 BYUKMGPIDIWLAC-UHFFFAOYSA-N 0.000 description 1
- PMGZJNCIQHGNLT-UHFFFAOYSA-N 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid Chemical compound CC(C)(C)C(=O)OCOP(=O)(OCOC(=O)C(C)(C)C)C(S(O)(=O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 PMGZJNCIQHGNLT-UHFFFAOYSA-N 0.000 description 1
- GUSVHVVOABZHAH-OPZWKQDFSA-N 1aw8p77hkj Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GUSVHVVOABZHAH-OPZWKQDFSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- UJGBTZUTZSMGCO-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC UJGBTZUTZSMGCO-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical class C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RHYFQVRDNPXOLV-MMVSWEMESA-N CC([C@@H](C(C[O](C)=C)OC12CC1)O)[C@H]2[O](C)=C Chemical compound CC([C@@H](C(C[O](C)=C)OC12CC1)O)[C@H]2[O](C)=C RHYFQVRDNPXOLV-MMVSWEMESA-N 0.000 description 1
- CVNOBBOJPADNCE-UHFFFAOYSA-N CCCCC(CCCC)(C1)NC(c2cccc(N)c2)c2cc(N(C)C)ccc2S1(=O)=O Chemical compound CCCCC(CCCC)(C1)NC(c2cccc(N)c2)c2cc(N(C)C)ccc2S1(=O)=O CVNOBBOJPADNCE-UHFFFAOYSA-N 0.000 description 1
- WXBDJDKCYUUCHT-XMMPIXPASA-N CCCCC(CCCC)(C1)N[C@H](c2cccc(NC(N)=O)c2)c2cc(N(C)C)ccc2S1(=O)=O Chemical compound CCCCC(CCCC)(C1)N[C@H](c2cccc(NC(N)=O)c2)c2cc(N(C)C)ccc2S1(=O)=O WXBDJDKCYUUCHT-XMMPIXPASA-N 0.000 description 1
- AQONHPNIZDNAGR-IRPNZFJTSA-N CCCCC(CCCC)(C1)N[C@H](c2cccc(NC(N[C@@H]([C@@H]([C@H]3O)O)OC(CO)[C@H]3O)=O)c2)c2cc(N(C)I)ccc2S1(=O)=O Chemical compound CCCCC(CCCC)(C1)N[C@H](c2cccc(NC(N[C@@H]([C@@H]([C@H]3O)O)OC(CO)[C@H]3O)=O)c2)c2cc(N(C)I)ccc2S1(=O)=O AQONHPNIZDNAGR-IRPNZFJTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical class 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 235000014168 granola/muesli bars Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003566 lomitapide Drugs 0.000 description 1
- QKVKOFVWUHNEBX-UHFFFAOYSA-N lomitapide mesylate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2C2=CC=CC=C2C1(C(=O)NCC(F)(F)F)CCCCN(CC1)CCC1NC(=O)C1=CC=CC=C1C1=CC=C(C(F)(F)F)C=C1 QKVKOFVWUHNEBX-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- LYAUICDWKQJAGX-UHFFFAOYSA-N n-(7-hydroxy-2,2,4,6-tetramethyl-1,3-dihydroinden-1-yl)-2-[4-(3-methoxyphenyl)piperazin-1-yl]acetamide Chemical compound COC1=CC=CC(N2CCN(CC(=O)NC3C(CC4=C3C(=C(C)C=C4C)O)(C)C)CC2)=C1 LYAUICDWKQJAGX-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- LXEDKSZTPGCEPU-UHFFFAOYSA-N n-[2-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound O=C1N(C)N=C2CCN(C(=O)C(NC(=O)C3C(C4=CC=CC=C4CC3)N)C=3C=CC(Cl)=CC=3)CC21CC1=CC=CC=C1 LXEDKSZTPGCEPU-UHFFFAOYSA-N 0.000 description 1
- DIQDKUNCSVFGHH-UHFFFAOYSA-N n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 DIQDKUNCSVFGHH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- YDCVQGAUCOROHB-UHFFFAOYSA-N oxadiazolidine-4,5-dione Chemical class O=C1NNOC1=O YDCVQGAUCOROHB-UHFFFAOYSA-N 0.000 description 1
- IBWLAJWLPGDDNE-UHFFFAOYSA-N oxalic acid propanal Chemical compound C(C(=O)O)(=O)O.C(CC)=O IBWLAJWLPGDDNE-UHFFFAOYSA-N 0.000 description 1
- VWMZIGBYZQUQOA-QEEMJVPDSA-N pamaqueside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC(=O)[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWMZIGBYZQUQOA-QEEMJVPDSA-N 0.000 description 1
- 229950005482 pamaqueside Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ZAOPBCHLHBOUPR-UHFFFAOYSA-N tert-butyl 1-[2-[di(propan-2-yl)amino]ethylcarbamoyl]-6-phenylmethoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2C(C(=O)NCCN(C(C)C)C(C)C)N(C(=O)OC(C)(C)C)CCC2=CC=1OCC1=CC=CC=C1 ZAOPBCHLHBOUPR-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229950004437 tiqueside Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- 229940077935 zinc phosphate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
본 발명은 치환된 1,4-벤조티아제핀 1,1-디옥사이드 유도체 및 생리학적으로 허용되는 이의 염에 관한 것이다.
1,4-벤조티아제핀 1,1-디옥사이드 유도체, 및 고지혈증, 동맥경화증 및 고콜레스테롤혈증을 치료하기 위한 이의 용도는 이미 기재되어 있다[참조: EP 1169313].
본 발명의 목적은 EP 1169313에 기재된 화합물에 비해 상당히 우수한 효능을 갖는 화합물을 제공하는 것이다.
따라서, 본 발명은 화학식 A의 화합물 및 약제학적으로 허용되는 이의 염에 관한 것이다.
이들은 출발 화합물 또는 기본 화합물보다 더 수용성이기 때문에 약제학적으로 허용되는 염은 의약용으로 특히 적합하다. 이들 염은 약제학적으로 허용되는 음이온 또는 양이온을 가져야 한다. 본 발명에 따르는 화합물의 적합한 약제학적으로 허용되는 산 부가염은 무기산, 예를 들면, 염산, 브롬화수소산, 인산, 메타인산, 질산 및 황산의 염 및 유기산, 예를 들면, 아세트산, 벤젠설폰산, 벤조산, 시트르산, 에탄설폰산, 푸마르산, 글루콘산, 글리콜산, 이세티온산, 락트산, 락토비온산, 말레산, 말산, 메탄설폰산, 석신산, p-톨루엔설폰산 및 타르타르산의 염이다.
약제학적으로 허용되지 않는 음이온을 함유하는 염(예: 트리플루오로아세테이트)이 또한 약제학적으로 허용되는 염을 제조하거나 정제하기 위해 유용한 중간체로서 및/또는 비치료용, 예를 들면, 시험관 용도로 사용하기 위해 본 발명의 범위에 속한다.
본 발명에 따르는 화합물은 또한 상이한 다형으로, 예를 들면, 무정형 및 결정형 다형으로 존재할 수 있다. 본 발명에 따르는 모든 다형은 본 발명의 범위 내에 속하고 본 발명의 또 다른 양상이다.
다음 설명에서, "화학식 A에 따르는 화합물(들)"이라고 하는 것은 모두 상기한 바와 같이 화학식 A의 화합물 및 이의 염 및 용매화물에 관한 것이다.
화학식 A의 화합물은 또한 다른 활성 화합물과 함께 투여될 수 있다.
목적하는 생물학적 효과를 성취하기 위해서 요구되는 화학식 A에 따르는 화합물의 양은 다수의 인자, 예를 들면, 선택된 특정 화합물, 의도되는 용도, 투여 유형 및 환자의 임상 상태에 좌우된다. 일반적으로, 1일 투여량의 범위는 0.01mg 내지 100mg(통상적으로 0.05mg 내지 50mg)/체중(kg)/일, 예를 들면, 0.1 내지 10mg/kg/일이다.
경구 투여될 수 있는 단일 투여 제형, 예를 들면, 정제 또는 캡슐제는, 예를 들면, 1.0 내지 1000mg, 통상적으로 10 내지 600mg을 함유할 수 있다. 화학식 A에 따르는 화합물은 그 자체가 상기 질환을 치료하기 위한 화합물로서 사용될 수 있지만, 바람직하게는 허용되는 담체와 함께 약제학적 조성물의 형태로 존재한다. 담체는 물론 조성물의 다른 성분들과 상용성이고 환자의 건강에 유해하지 않다는 점에서 허용되는 것이어야 한다. 담체는 고형 또는 액체 또는 둘 다일 수 있고, 바람직하게는, 단일 투여형으로서, 예를 들면, 활성 화합물을 0.05 내지 95중량% 함유할 수 있는 정제로서 화합물과 함께 제형된다. 화학식 A에 따르는 다른 화합물을 포함하는 다른 약제학적으로 활성 물질이 또한 존재할 수 있다. 본 발명에 따르는 약제학적 조성물은 본질적으로 성분들을 약리학적으로 허용되는 담체 물질 및/또는 보조제 물질과 함께 혼합하는 것으로 이루어진 공지된 약제학적 방법 중 하나를 사용하여 제조할 수 있다.
본 발명에 따르는 약제학적 조성물은 가장 적합한 투여 방식이 각각의 개별적인 경우에 치료될 질환의 특징 및 중증도 및 각각의 경우에 사용되는 화학식 A에 따르는 화합물의 특성에 좌우되는 경우에도 경구 및 경구적(예: 설하) 투여에 적합하다. 당의 제형 및 당의 서방출 제형도 본 발명의 범위에 속한다. 내산성 및 내위액성(gastric juice-resistant)인 제형이 바람직하다. 적합한 내위액성 코팅으로는 셀룰로스 아세테이트 프탈레이트, 폴리비닐 아세테이트 프탈레이트, 하이드록시프로필메틸 셀룰로스 프탈레이트 및 메타크릴산과 메틸 메타크릴레이트의 음이온성 중합체가 있다.
경구 투여용으로 적합한 약제학적 화합물은 독립된 단위로, 예를 들면, 각각의 경우에 화학식 A에 따르는 화합물을 특정량 함유하는 캡슐제, 카세제, 로젠지제 또는 정제로; 산제 또는 과립제로서; 수용성 또는 비수용성 액체 중의 용액제 또는 현탁액제로서; 또는 수중유 또는 유중수 유액으로서 존재할 수 있다. 이미 언급한 바와 같이, 이들 조성물은 활성 화합물과 담체(이는 하나 이상의 추가 성분으로 이루어질 수 있다)를 접촉시키는 단계를 포함하는 모든 적합한 약제학적 방법을 사용하여 제조할 수 있다. 일반적으로, 조성물은 활성 화합물과 액체 및/또는 미분 고형 담체를 균일하고 균질하게 혼합한 후, 필요한 경우, 생성물을 성형함으로써 제조한다. 따라서, 정제는, 예를 들면, 필요한 경우, 하나 이상의 추가 성분과 함께 압축되거나 성형되는 화합물의 분말 또는 과립을 통해 제조할 수 있다. 압축 정제는 적합한 기계에서, 필요한 경우, 결합제, 윤활제, 불활성 희석제 및/또는 하나의(수 개의) 계면활성제/분산제(들)과 함께 화합물을 자유 유동 형태로, 예를 들 면, 분말 또는 과립으로 타정함으로써 제조할 수 있다. 성형 정제는 불활성 액체 희석제에 의해 습윤된 분말 화합물을 적합한 기계에서 성형함으로써 제조할 수 있다.
경구적(설하) 투여에 적합한 약제학적 조성물로는 화학식 A에 따르는 화합물을 향미제, 통상적으로 수크로즈 및 아라비아 고무 또는 트라가칸트와 함께 함유하는 로젠지제, 및 불활성 염기, 예를 들면, 젤라틴 및 글리세롤 또는 수크로스 및 아라비아 고무 속에 화합물을 포함하는 파스틸(pastil)이 있다.
본 발명에 따르는 약제학적 조성물의 추가의 양태는 적합한 금속염, 예를 들면, 칼슘, 알루미늄, 철, 구리, 아연, 마그네슘, 망간 또는 아연염을 포함한다. 칼슘염 및 아연염, 예를 들면, 인산칼슘, 칼슘 락테이트, 탄산칼슘, 칼슘 글루코네이트, 칼슘 아세테이트, 인산아연, 아연 락테이트, 탄산아연, 아연 글루코네이트 또는 아연 아세테이트가 바람직하다. 이들 염을 약제학적 조성물에 첨가함으로써 환자에게서 설사 발생을 감소시키거나 방지할 수 있다.
다음은 배합 제제용 추가 활성 화합물로서 사용하기에 적합하다: 로텐 리스트(Roten Liste)[Red List] 2005의 12장에 명명되어 있는 모든 항당뇨병약. 이들은 특히 효과를 상승적으로 향상시키려는 목적으로 본 발명에 따르는 화학식 A의 화합물과 배합될 수 있다. 활성 화합물 배합물은 활성 화합물을 환자에게 따로 투여하거나 이들을 수 개의 활성 화합물이 하나의 약제학적 제제에 존재하는 배합 제제의 형태로 투여함으로써 투여할 수 있다. 아래에서 언급되는 대부분의 활성 화합물은 문헌[참조: USP Dictionary of USAN & International Drug Names, US Pharmacopeia, Rockville 2001]에 기재되어 있다.
항당뇨병약에는 인슐린 및 인슐린 유도체, 예를 들면, 란투스(Lantus®)[참조: www.lantus.com] 또는 HMR 1964, 신속 작용성 인슐린(참조: 6,221,633), GLP-1 유도체, 예를 들면, 노보 노르디스크 아/에스(Novo Nordisk A/S)가 WO 98/08871에 기재하고 있는 것들, 질랜드(Zealand)가 WO/04156에 기재하고 있는 것들 및 뷰포-입센(Beaufour-Ipsen)이 WO 00/34331에 기재하고 있는 것들이 포함되고, 경구 활성 혈당 강하 활성 화합물도 포함된다.
경구 활성 혈당 강하 활성 화합물에는 바람직하게는 설포닐우레아, 비구아니딘(biguanidines), 메글리티니드(meglitinides), 옥사디아졸리딘디온(oxadiazolidinediones), 티아졸리딘디온(thiazolidinediones), 글루코시다제 및 글리코겐 포스포릴라제 억제제, 글루카곤 길항제, GLP-1 작용제, 칼륨 채널 개방제(opener), 예를 들면, 노보 노르디스크 아/에스가 WO 97/26265 및 WO 99/03861에 기재하고 있는 것들, 인슐린 민감제, 글루코스신합성 및/또는 당원분해의 자극에 관여하는 간 효소의 억제제, 글루코스 흡수 조절자, 글루코스 수송 및 글루코스 재흡수, 지방 대사를 변경시키는 화합물, 예를 들면, 항고지혈증 활성 화합물 및 항지혈증(antilipidaemic) 활성 화합물, 식품 흡수를 감소시키는 화합물, PPAR 작용제 및 PXR 작용제, 및 베타 세포에서 ATP 의존성 칼륨 채널에 대해 작용하는 활성 화합물이 포함된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 HMGCoA 리덕타제 억제제, 예를 들면, 심바스타틴(simvastatin), 플루바스타틴(fluvastatin), 프라바스타 틴(pravastatin), 로바스타틴(lovastatin), 아토르바스타틴(atorvastatin), 세리바스타틴(cerivastatin) 또는 로수바스타틴(rosuvastatin)과 함께 투여된다.
본 발명의 한 양태로서, 화학식 I의 화합물은 콜레스테롤 흡수 억제제, 예를 들면, 에제티미브(ezetimibe), 티퀘시드(tiqueside), 파마퀘시드(pamaqueside) 또는 PCT/EP 2004/00269, PCT/EP 2003/05815, PCT/EP 2003/05814, PCT/EP 2003/05816, EP 0114531 또는 US 6,498,156에 기재되어 있는 화합물과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 PPAR 감마 작용제, 예를 들면, 로시클리타존(rosiglitazone), 피오글리타존(pioglitazone), JTT-501 또는 GI 262570과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 PPAR 알파 작용제, 예를 들면, GW 9578 또는 GW 7647과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 혼합된 PPAR 알파/감마 작용제, 예를 들면, GW 1536, AVE 8042, AVE 8134 또는 AVE 0847 또는 PCT/US 00/11833, PCT/US 00/11490 또는 WO 03/020269에 기재되어 있는 것들과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 피브레이트(fibrate), 예를 들면, 페노피브레이트(fenofibrate), 클로피브레이트(clofibrate) 또는 베자피브레이트(bezafibrate)와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 MTP 억제제, 예를 들면, 임플 리타피드(implitapide), BMS-201038 또는 R-103757과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 CETP 억제제, 예를 들면, JTT-705와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 중합체성 담즙산 흡착제, 예를 들면, 콜레스티라민(cholestyramine) 또는 콜레세벨람(colesevelam)과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 LDL 수용체 유도 인자(참조: US 6,342,512)와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 ACAT 억제제, 예를 들면, 아바시미베(avasimibe)와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 항산화제, 예를 들면, OPC-14117과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 지단백 리파제 억제제, 예를 들면, NO-1886과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 ATP 시트레이트 리아제 억제제, 예를 들면, SB-204990과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 스쿠알렌 신타제 억제제, 예를 들면, BMS-188494와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 지단백(들) 길항제, 예를 들면, CI-1027 또는 니코틴산과 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 리파제 억제제, 예를 들면, 오를리스타트(orlistat)와 함께 투여된다.
본 발명의 한 양태로서, 화학식 A의 화합물은 인슐린과 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 설포닐우레아, 예를 들면, 톨부타미드(tolbutamide), 글리벤클라미드(glibenclamide), 글리피지드(glipizide) 또는 글리메피리드(glimepiride)와 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 비구아니드(biguanide), 예를 들면, 메트포르민(metformin)과 함께 투여된다.
또 다른 양태로서, 화학식 A의 화합물은 메글리티니드(meglitinide), 예를 들면, 레파글리니드(repaglinide)와 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 티아졸리딘디온, 예를 들면, 트로글리타존(troglitazone), 시글리타존(ciglitazone), 피오글리타존(pioglitazone), 로시글리타존(rosiglitazone) 또는 닥터 레디스 리서치 파운데이션(Dr. Reddy's Research Foundation)이 WO 97/41097에 기재하고 있는 화합물, 특히 5-[[4-[(3,4-디하이드로-3-메틸-4-옥소-2-퀴나졸리닐메톡시]페닐]메틸]-2,4-티아졸리딘디온과 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 α-글루코시다제 억제제, 예를 들면, 미글리톨(miglitol) 또는 아카르보스(acarbose)와 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 아데노신 A1 작용제, 예를 들면, EP 0912520 또는 PCT/EP06749에 기재되어 있는 것들과 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 베타 세포의 ATP-의존성 칼륨 채널에 대해 작용하는 활성 화합물, 예를 들면, 톨부타미드(tolbutamide), 글리벤클라미드(glibenclamide), 글리피지드(glipizide), 글리메피리드 또는 레파글리니드(repaglinide)와 함께 투여된다.
한 양태로서, 화학식 A의 화합물은 상기 화합물들 중의 1개를 초과하는 화합물과 함께, 예를 들면, 설포닐우레아와 메트포르민, 설포닐우레아와 아카르보스, 레파글리니드와 메트포르민, 인슐린과 설포닐우레아, 인슐린과 메트포르민, 인슐린과 트로글리타존, 인슐린과 로바스타틴 등과 함께 투여된다.
또 다른 양태로서, 화학식 A의 화합물은 CART 조절자(참조: "cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A. et al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558), NPY 길항제, 예를 들면, 나프탈렌-1-설폰산-{4-[(4-아미노퀴나졸린-2-일아미노)메틸]사이클로헥실-메틸}아미드 하이드로클로라이드(CGP 71683A), 칸나비노이드 수용체 1 길항제(참조: EP 0656354, WO 00/15609 또는 WO 02/076949), MC4 작용제(예: 1-아미노-1,2,3,4-테트라하이드로나프탈렌-2-카복실산 [2-(3a-벤질-2-메틸-3-옥소-2,3,3a,4,6,7-헥사하이드로피라졸로[4,3-c]피리딘-5-일)-1-(4-클로로페닐)-2-옥소에틸]아미드; (WO 01/91752)), 오렉신 길항제(예: 1-(2-메틸벤즈옥사졸-6-일)-3-[1,5]나프티리딘-4-일 우레아 하이드로클로라이드(SB-334867-A)), H3 작용제(3-사이클로헥실-1-(4,4-디메틸-1,4,6,7-테트라하이드로이미다조[4,5-c]피리딘-5-일)-프로판-1-온 옥살산 염(WO 00/63208)); TNF 작용 제, CRF 길항제(예: [2-메틸-9-(2,4,6-트리메틸페닐)-9H-1,3,9-트리아자플루오렌-4-일]디프로필아민(WO 00/66585)), CRF BP 길항제(예: 우로코르틴(urocortin)), 우로코르틴 작용제, β3-작용제(예: 1-(4-클로로-3-메탄설포닐메틸페닐)-2-[2-(2,3-디메틸-1H-인돌-6-일옥시)에틸아미노]에탄올 하이드로클로라이드(WO 01/83451)), MSH(멜라닌 세포 자극 호르몬) 작용제, MCH(멜라닌-농축 호르몬) 수용체 길항제(참조: WO 03/15769), CCK-A 작용제(예: {2-[4-(4-클로로-2,5-디메톡시페닐)-5-(2-사이클로헥실에틸)티아졸-2-일카바모일]-5,7-디메틸인돌-1-일}아세트산 트리플루오로아세트산 염(WO 99/15525) 또는 SR-146131(WO 0244150) 또는 SSR-125180), 세로토닌 재흡수 억제제(예: 덱스펜플루라민(dexfenfluramine)), 혼합 세로토닌성 및 노르아드레날린성 화합물(예: WO 00/71549), 5HT 작용제, 예를 들면, 1-(3-에틸벤조푸란-7-일)피페라진 옥살산염(WO 01/09111), 봄베신(bombesin) 작용제, 갈라닌 길항제, 성장 호르몬(예: 사람 성장 호르몬), 성장 호르몬 방출 화합물(3급-부틸 6-벤질옥시-1-(2-디이소프로필아미노에틸카바모일)-3,4-디하이드로-1H-이소퀴놀린-2-카복실레이트(WO 01/85695)), TRH 작용제(참조: EP 0462884), 디커플링(decoupling) 단백질 2 또는 단백질 3 조절자, 렙틴 작용제(참조: Lee, Daniel W.; Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881), DA 작용제(브로모크립틴(bromocriptine), 도프렉신(doprexin)), 리파제/아밀라제 억제제(예: WO 00/40569), PPAR 조절자(예: WO 00/78312), 11β-HSD1(11-베타-하이드록시스테로이드데하이드로게나제 유형 1) 억 제제[참조: WO 01/90094 또는 문헌(T. Barf et al., J. Med. Chem. (2002), 45, 3813-3815], 아세틸-CoA 카복실라제(ACC; 참조: WO 99/46262) 억제제, 디펩티딜펩티다제 IV(DPP-IV; 참조: EP 1259246) 억제제, RXR 조절자 또는 TR-β-작용제와 함께 투여된다.
본 발명의 한 양태로서, 다른 활성 화합물은 렙틴이다[참조: "Perspectives in the therapeutic use of leptin", Salvador, Javier; Gomez-Ambrosi, Javier; Fruhbeck, Gema, Expert Opinion on Pharmacotherapy (2001), 2(10), 1615-1622)].
한 양태로서, 다른 활성 화합물은 덱삼페타민(dexamphetamine) 또는 암페타민(amphetamine)이다.
한 양태로서, 다른 활성 화합물은 펜플루라민(fenfluramine) 또는 덱스펜플루라민(dexfenfluramine)이다.
또 다른 양태로서, 다른 활성 화합물은 시부트라민(sibutramine)이다.
한 양태로서, 다른 활성 화합물은 오를리스타트(orlistat)이다.
한 양태로서, 다른 활성 화합물은 마진돌(mazindol) 또는 펜테르민(phentermine)이다.
한 양태로서, 화학식 A의 화합물은 밸러스트 물질(ballast substances), 바람직하게는 불용성 밸러스트 물질(예: 카로브(carob)/카로맥스(Caromax®))(참조: Zunft H J; et al., Carob pulp preparation for treatment of hypercholesterolemia, ADVANCES IN THERAPY (2001 Sep-Oct), 18(5), 230-6)과 함께 투여된다. 카로맥스는 독일 65926 프랑크푸르트/마인 인두스트리파크 훽스트에 소재하는 누트리노파, 누트리티온 스페시알티스 운트 푸드 인그레딘츠 게엠베하(Nutrinova, Nutrition Specialties & Food Ingredients GmbH)의 카로브 함유 제품이다. 카로맥스와의 배합은 하나의 제제에서 달성될 수 있거나 화학식 A의 화합물과 카로맥스를 따라 투여함으로써 달성될 수 있다. 이와 관련하여, 카로맥스는 또한 식료품의 형태로, 예를 들면, 빵, 케익 및 빵과자 또는 뮤즐리 바(muesli bar) 형태로 투여될 수 있다.
본 발명에 따르는 화합물과 하나 이상의 상기 화합물 및, 필요한 경우, 하나 이상의 추가의 약리학적 활성 물질과의 각각 적합한 배합물도 본 발명의 보호 범위에 속하는 것으로 간주됨을 이해할 것이다.
실시예 A
화학식 A
화합물(A)는 다음과 같이 제조하였다.
화합물(1a)의 합성:
에난티오머적으로 순수한 화합물(1a)를 라세미체 아닐리드(1)(EP 1169313 화합물 8a/b)로부터 키랄팩 AS-H96을 사용하여 이동상 n-헵탄/메탄올/에탄올(10/1/1)과 0.1% DEA로 키랄 크로마토그래피하여 수득한다. THF/EA/n-헵탄으로부터 결정화함으로써 화합물(1a)를 더욱 더(ee 99.9%) 정제시킬 수 있다. 유토머(eutomer)는 포지티브 광학 회전성을 갖고, 절대 입체화학은 단일 결정 X선 구조로 측정되었다.
화합물(3)의 합성:
실온에서 아닐리드(1a) 6g과 이소시아네이트(2)(Synlett 2003, 1, 47-50) 7.5g을 메틸렌 클로라이드 150ml에 용해시킨다. 실온에서 1시간 후, 혼합물을 농축시키고, 잔사를 섬광 크로마토그래피로 정제한다. 화합물(3)을 무색 고체로서 10.5g(95%) 수득한다. TLC(n-헵탄/에틸 아세테이트 1:2). Rf=0.3. C40H56N4O12S(816.98). MS(M+H)+=817.33.
화합물(A)의 합성:
화합물(3) 9.7g을 메탄올 120ml와 트리에틸아민 40ml에 용해시키고, 실온에서 16시간 동안 방치한다. 용액을 농축시키고, 잔사를 고온 에틸 아세테이트 60ml에 용해시킨다. 실온으로 냉각시킨 후, 에틸 아세테이트/n-헵탄(4:1) 50ml를 가한다. 현탁액을 30분 동안 교반하고, 침전물을 흡인 여과한 후, 에틸 아세테이트/n-헵탄(4:1) 30ml로 세척한다. 화합물(A)를 무정형 고체로서 7.01g(91%) 수득하고 모액(화합물(A) 40 내지 50% 함유) 450mg을 수득한다. TLC(메틸렌 클로라이드/메탄올/진한 암모니아 30/10/3). Rf=0.5. C32H48N4O8S(648.83). MS(M+H)+=649.26.
본 발명에 따르는 화합물(A)의 생물학적 시험을 시험관내 IBAT 억제 시험을 사용하여 수행하였다. 당해 시험은 재조합적으로 발현된 사람 나트륨 의존성 회장 담즙산 수송자의 수송 활성에 대한 본 발명에 따르는 화합물의 효과를 조사한다(IBAT=회장 Na+/담즙산 콘트랜스포터(contransporter), ASBT=정점(apical) 나트륨 의존성 담즙산 수송자, SLC10A2=용질 담체족 10, 멤버 2).
시험관내 IBAT 억제 시험을 위한 제조 및 실시:
1. 사람 IBAT에 대한 발현 벡터의 클로닝
사람 IBTA의 cDNA(상보적 데옥시리보핵산)를, 예를 들면, 조셉 샘브룩(Jeseph Sambrook)과 데이비드 러셀(David Russell)의 분자 클로닝: 실험실 매뉴얼에 기재되어 있는 분자 생물학의 표준 방법을 사용하여 클로닝하고, 인비트로겐(Invitrogen)으로부터 입수한 pcDNA1 벡터에 도입시켰다. 삽입물의 후속 서열화는 도슨 피.에이.(Dawson P.A.)가 기재하고 유전자은행 서열 데이타은행(GenBank sequence databank)(유전자은행 승인 번호: U10417)에 기탁된 사람 IBAT에 대한 염기 서열의 염기 599 내지 1645와 완전히 일치함을 나타냈다. 염기 599 내지 1645는 사람 IBAT의 완전한 코딩 영역에 상응한다.
2. 사람 IBAT를 구성적으로 발현하는 재조합 세포주의 제조
사람 IBAT에 대한 발현 벡터를 안정한 트랜스펙션(transfection)을 통해 CHO(중국 햄스터 난소) 세포에 도입시켰다. 단일 세포 클론을 선택하기 위해서, 제네티신(geneticin) 400㎍/㎖를 세포 배양 배지(10% 우태 혈청, 100단위/ml 페니실린, 100단위/ml 스트렙토마이신이 보충된 햄스(Ham's) F12 배지)에 가하였다. 당해 선택으로 인한 단일 세포 클론의 기능성을 방사선 표지된 토로콜산([3H]-TCA)에 대한 이들의 흡수 활성을 통해 시험하였다. 후속적으로 CHO-hIBAT로서 나타내는, [3H]-TCA에 대해 가장 높은 흡수 활성을 갖는 세포 클론을 추가 시험을 위해서 선택하고 제네티신 400㎍/㎖의 존재하에 추가로 배양시켰다.
3. 본 발명에 따르는 화합물의 세포로의 토로콜산의 IBAT-의존성 흡수에 대한 억제 효과의 측정
CHO-hIBAT 세포를 폴리-D-라이신 피복된 96웰 플레이트에 세포 배양 배지 속의 웰당 40,000개의 세포의 농도로 심고 24시간 동안 배양시켰다. 이어서, 세포를 나트륨 비함유 수송 검정 완충액(140mM 콜린 클로라이드, 2mM 염화칼륨, 1mM 염화마그네슘, 1mM 염화칼슘, 10mM HEPES/Tris, pH 7.5)으로 1회 세척하고, 네거티브 대조군으로서 나트륨 비함유 수송 검정 완충액 또는 포지티브 대조군으로서 나트륨 함유 수송 검정 완충액(140mM 염화나트륨, 2mM 염화칼륨, 1mM 염화마그네슘, 1mM 염화칼슘, 10mM HEPES/Tris, pH 7.5)을 사용하여 실온에서 30분 동안 배양하였다. 동시에, 시험 웰을 상이한 농도의 시험될 화합물의 존재하에 나트륨 함유 수송 검정 완충액 속에서 실온에서 30분 동안 배양하였다. 디메틸 설폭사이드 중의 10mM 원액을 사용하여 시험 물질을 수송 검정 완충액(40㎕/웰) 속에서 적합하게 희석시켰다. 이어서, 방사선 표지된 토로콜산([3H]-TCA)과 표지되지 않은 토로콜산의 혼합물 10㎕/웰을 첨가하여 시험을 개시시켰다. 시험에서 토로콜산의 최종 농도는 10μM이었다. 실온에서 60분 배양한 후, 나트륨 비함유 수송 검정 완충액(4℃) 100㎕/웰을 첨가하여 반응을 중단시키고, 각각의 웰을 나트륨 비함유 수송 검정 완충액으로 3회 세척하였다. 마지막으로, 신틸레이션 유체 100㎕를 각각의 웰에 가하고, 세포로 흡수된 방사선을 왈락(Wallac)으로부터 입수한 마이크로베타(MicroBeta) 신틸레이션 마이크로플레이트 판독기로 측정하였다.
시험 화합물의 반치(half-maximal) 억제 효과(IC50 값, 억제 농도 50)를 다음과 같이 측정하였다:
1. 0% 억제값을 측정한다. 이는 물질의 부재하에 나트륨 함유 수송 검정 완충액 속에서 측정된다.
2. 100% 억제값을 측정한다. 이는 물질의 부재하에 나트륨 비함유 수송 검정 완충액 속에서 측정된 값이다.
3. 각종 농도의 시험될 화합물의 존재하에 수행된 측정의 억제값(%)을 계산한다. 이들 값을 사용하여 토로콜산 흡수율이 50% 감소되는 화합물 농도를 측정할 수 있다.
실시예 A의 경우, IC50(사람 IBAT)이 0.057μM인 것으로 밝혀졌다.
비교를 위해서, EP 1169313으로부터의 구조적으로 가장 유사한 화합물을 또한 측정하였다. 화학식 11a의 (실시예 5로부터의) 화합물(11a)의 경우, IC50(사람 IBAT)이 0.319μM인 것으로 밝혀졌다.
EP 1169313으로부터의 화합물에 대한 당해 비교 실시예에 비해 본 발명에 따르는 화합물(A)의 활성이 560% 더 높다.
Claims (12)
- 제1항에 따르는 화합물을 포함하는 약제.
- 제1항에 따르는 화합물과 하나 이상의 추가의 활성 화합물을 포함하는 약제.
- 제3항에 있어서, 추가의 활성 화합물로서 지질 대사를 정상화하는 하나 이상의 화합물을 포함하는 약제.
- 제3항 또는 제4항에 있어서, 추가의 활성 화합물로서 하나 이상의 항당뇨병약, 혈당강하 활성 화합물, 지방 억제(anti-adipose) 약물, 식욕감퇴제, HMG-CoA-리덕타제 억제제, 콜레스테롤 흡수 억제제, PPAR 감마 작용제, PPAR 알파 작용제, PPAR 알파/감마 작용제, 피브레이트, MTP 억제제, CETP 억제제, 중합체성 담즙산 흡착제, LDL 수용체 유도 인자, ACAT 억제제, 항산화제, 지단백질 리파제 억제제, ATP 시트레이트 리아제 억제제, 스쿠알렌 신테타제 억제제, 지단백질(a) 길항제, 리파제 억제제, 인슐린, 설포닐우레아, 비구아니드, 메글리티니드, 티아졸리딘디온, α-글루코시다제 억제제, 베타 세포의 ATP-의존성 칼륨 채널에 대해 작용하는 활성 화합물, CART 작용제, NPY 작용제, 칸나비노이드 수용체 1 길항제, MCH 수용체 길항제, MC4 작용제, 오렉신 작용제, H3 작용제, TNF 작용제, CRF 작용제, CRF BP 길항제, GLP-1 유도체, 우로코르틴 작용제, β3 작용제, MSH(멜라닌 세포 자극 호르몬) 작용제, CCK-A 작용제, 세로토닌 재흡수 억제제, 혼합 세로토닌 및 노르아드레날린성 화합물, 5HT 작용제, 봄베신 작용제, 갈라닌 길항제, 성장 호르몬, 성장 호르몬 방출 화합물, TRH 작용제, 디커플링 단백질-2 또는 -3 조절자, 렙틴 작용제, DA 작용제(브로모크립틴, 도프렉신), 리파제/아밀라제 억제제, 11β-HSD1 억제제, ACC 억제제, DPP-IV 억제제, PPAR 조절자, RXR 조절자 또는 TR-β작용제 또는 암페타민을 포함하는 약제.
- 제2항 내지 제5항 중의 어느 한 항에 있어서, 추가의 보조제로서 하나 이상의 금속염을 포함하는 약제.
- 제1항에 있어서, 지질 대사 질환 치료용 약제로서 사용하기 위한 화합물.
- 활성 화합물과 약제학적으로 허용되는 담체를 혼합하고, 혼합물을 투여하기에 적합한 형태로 형성시킴을 포함하는, 제1항에 따르는 화합물을 포함하는 약제의 제조방법.
- 고지혈증 치료용 약제를 제조하기 위한, 제1항에 따르는 화합물의 용도.
- 혈청 콜레스테롤 농도 저하용 약제를 제조하기 위한, 제1항에 따르는 화합물의 용도.
- 동맥경화증 치료용 약제를 제조하기 위한, 제1항에 따르는 화합물의 용도.
- 인슐린 내성 치료용 약제를 제조하기 위한, 제1항에 따르는 화합물의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005033099A DE102005033099A1 (de) | 2005-07-15 | 2005-07-15 | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
DE102005033099.1 | 2005-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080031738A true KR20080031738A (ko) | 2008-04-10 |
Family
ID=36997833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087001183A KR20080031738A (ko) | 2005-07-15 | 2006-07-13 | 1,4-벤조티아제핀 1,1-디옥사이드 유도체, 이의 제조방법,이를 포함하는 약제 및 고지혈증 치료제로서의 이의 용도 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7615536B2 (ko) |
EP (1) | EP1912960A1 (ko) |
JP (1) | JP2009501177A (ko) |
KR (1) | KR20080031738A (ko) |
CN (1) | CN101223151A (ko) |
AU (1) | AU2006272042A1 (ko) |
BR (1) | BRPI0613462A2 (ko) |
CA (1) | CA2614524A1 (ko) |
DE (1) | DE102005033099A1 (ko) |
IL (1) | IL188608A0 (ko) |
MA (1) | MA29619B1 (ko) |
MX (1) | MX2008000426A (ko) |
NO (1) | NO20080789L (ko) |
NZ (1) | NZ565292A (ko) |
RU (1) | RU2008105756A (ko) |
TW (1) | TW200745069A (ko) |
UY (1) | UY29675A1 (ko) |
WO (1) | WO2007009655A1 (ko) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006299091A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
DE102006053636B4 (de) | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
EP2083832B1 (de) | 2006-11-14 | 2011-01-05 | Sanofi-Aventis Deutschland GmbH | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
CN105287604B (zh) | 2010-11-08 | 2019-07-09 | 阿尔比里奥公司 | 含ibat抑制剂和胆汁酸结合剂的药物组合 |
SG190029A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA2853285C (en) | 2011-10-28 | 2020-05-05 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
RU2750944C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
EP3413878B1 (en) | 2016-02-09 | 2021-04-14 | Albireo AB | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
EP3664782A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
ES2955799T3 (es) | 2019-02-06 | 2023-12-07 | Albireo Ab | Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares |
CA3127568A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
FI4069360T3 (fi) | 2019-12-04 | 2024-02-20 | Albireo Ab | Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina |
TW202134223A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2024121434A1 (en) | 2022-12-09 | 2024-06-13 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE441189B (sv) * | 1984-02-07 | 1985-09-16 | Boliden Ab | Forfarande for framstellning av metalliskt bly genom smeltreduktion |
PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
-
2005
- 2005-07-15 DE DE102005033099A patent/DE102005033099A1/de not_active Ceased
-
2006
- 2006-07-13 JP JP2008520794A patent/JP2009501177A/ja not_active Abandoned
- 2006-07-13 RU RU2008105756/04A patent/RU2008105756A/ru not_active Application Discontinuation
- 2006-07-13 BR BRPI0613462-9A patent/BRPI0613462A2/pt not_active Application Discontinuation
- 2006-07-13 KR KR1020087001183A patent/KR20080031738A/ko not_active Application Discontinuation
- 2006-07-13 CN CNA2006800258356A patent/CN101223151A/zh active Pending
- 2006-07-13 CA CA002614524A patent/CA2614524A1/en not_active Abandoned
- 2006-07-13 AU AU2006272042A patent/AU2006272042A1/en not_active Abandoned
- 2006-07-13 MX MX2008000426A patent/MX2008000426A/es not_active Application Discontinuation
- 2006-07-13 NZ NZ565292A patent/NZ565292A/en unknown
- 2006-07-13 WO PCT/EP2006/006848 patent/WO2007009655A1/de active Application Filing
- 2006-07-13 TW TW095125565A patent/TW200745069A/zh unknown
- 2006-07-13 EP EP06776211A patent/EP1912960A1/de not_active Withdrawn
- 2006-07-14 UY UY29675A patent/UY29675A1/es unknown
-
2008
- 2008-01-06 IL IL188608A patent/IL188608A0/en unknown
- 2008-01-07 US US11/970,281 patent/US7615536B2/en not_active Expired - Fee Related
- 2008-01-08 MA MA30556A patent/MA29619B1/fr unknown
- 2008-02-13 NO NO20080789A patent/NO20080789L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008105756A (ru) | 2009-08-20 |
DE102005033099A1 (de) | 2007-01-18 |
WO2007009655A1 (de) | 2007-01-25 |
MX2008000426A (es) | 2008-03-10 |
UY29675A1 (es) | 2007-02-28 |
US7615536B2 (en) | 2009-11-10 |
US20080207534A1 (en) | 2008-08-28 |
NZ565292A (en) | 2010-01-29 |
AU2006272042A1 (en) | 2007-01-25 |
NO20080789L (no) | 2008-02-13 |
CN101223151A (zh) | 2008-07-16 |
IL188608A0 (en) | 2008-04-13 |
BRPI0613462A2 (pt) | 2011-01-11 |
TW200745069A (en) | 2007-12-16 |
EP1912960A1 (de) | 2008-04-23 |
JP2009501177A (ja) | 2009-01-15 |
CA2614524A1 (en) | 2007-01-25 |
MA29619B1 (fr) | 2008-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20080031738A (ko) | 1,4-벤조티아제핀 1,1-디옥사이드 유도체, 이의 제조방법,이를 포함하는 약제 및 고지혈증 치료제로서의 이의 용도 | |
US20080207592A1 (en) | Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof | |
RU2339641C2 (ru) | Новые гетероциклические фторгликозидные производные, содержащие эти соединения лекарственные средства и их применение | |
RU2434003C2 (ru) | Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств | |
ZA200506708B (en) | Novel diphenyl azetidinone with improved physiological characteristics, corresponding production method, medicaments containing said compound and use of the latter | |
OA12805A (fr) | Dérivés d'acyl-4-carboxyphényluré¦, procédés pour les préparer et leur utilisation. | |
JP2008536838A (ja) | 置換された2−アミノアルキルチオベンゾイミダゾール、及び血糖レベルを減少させるためのその使用 | |
JP4838730B2 (ja) | シクロアルキル置換7−アミノ−4−キノロン−3−カルボン酸誘導体、その製造方法及び医薬としてのその使用 | |
JP4398859B2 (ja) | N−ベンゾイルウレイド桂皮酸誘導体、それらの製造法、およびそれらの使用 | |
US7470706B2 (en) | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | |
US7501440B2 (en) | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use | |
HRP20040931A2 (en) | Acyl-3-carboxyphenylurea derivatives, method for production and use thereof | |
DE10309929B4 (de) | Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |